• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[前列腺特异性抗原血清水平解读的局限性]

[Limitations on the interpretation of prostate-specific antigen serum levels].

作者信息

Sciarra A, Casale P, Di Nicola S, Di Chiro C, Colella D, Di Silverio F

机构信息

Dipartimento di Urologia U. Bracci, Università degli Studi di Roma, La Sapienza.

出版信息

Minerva Urol Nefrol. 1999 Jun;51(2):105-12.

PMID:10429421
Abstract

Recent data suggest that PSA expression can be directly influenced by some factors, independently from the variation in prostate cell growth. Some growth factors such as fibroblast growth factor, transforming growth factor beta and epidermal growth factor, seem to be directly involved in the regulation of mRNA-PSA expression, whereas androgens could have an indirect activity. On the basis of these experimental data, this review tries to analyze some limits of PSA and some recent data on the role of PSA-isoforms, in particular in the follow-up of prostate cancer patients submitted to radical prostatectomy or hormone-therapy. Moreover, relevant informations can be obtained analyzing the variance of PSA in patients submitted to intermittent androgen deprivation.

摘要

最近的数据表明,前列腺特异性抗原(PSA)的表达可直接受某些因素影响,而与前列腺细胞生长的变化无关。一些生长因子,如成纤维细胞生长因子、转化生长因子β和表皮生长因子,似乎直接参与mRNA-PSA表达的调节,而雄激素可能具有间接作用。基于这些实验数据,本综述试图分析PSA的一些局限性以及关于PSA异构体作用的一些最新数据,特别是在接受根治性前列腺切除术或激素治疗的前列腺癌患者的随访中。此外,通过分析接受间歇性雄激素剥夺治疗患者的PSA变化,可以获得相关信息。

相似文献

1
[Limitations on the interpretation of prostate-specific antigen serum levels].[前列腺特异性抗原血清水平解读的局限性]
Minerva Urol Nefrol. 1999 Jun;51(2):105-12.
2
Prostate-specific antigen as a marker of disease activity in prostate cancer.
Oncology (Williston Park). 2002 Sep;16(9):1218-24; discussion 1224, 1227-8 passim.
3
Prostate cancer update: 2005.前列腺癌最新进展:2005年
Curr Opin Oncol. 2006 May;18(3):284-8. doi: 10.1097/01.cco.0000219259.83585.f3.
4
The role of prostate-specific antigen in light of new scientific evidence.基于新科学证据看前列腺特异性抗原的作用。
Actas Urol Esp. 2013 Jun;37(6):324-9. doi: 10.1016/j.acuro.2013.01.009. Epub 2013 Apr 19.
5
[Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].[完全激素阻断与单纯激素阻断治疗前列腺癌的比较]
Arch Esp Urol. 2002 Sep;55(7):771-5.
6
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.前列腺特异性抗原失败后接受激素治疗的前列腺特异性抗原最低点与癌症特异性死亡率
J Clin Oncol. 2005 Sep 20;23(27):6556-60. doi: 10.1200/JCO.2005.20.966.
7
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].[欧洲泌尿外科学会前列腺癌指南。第二部分:晚期、复发性及去势抵抗性前列腺癌的治疗]
Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14.
8
The utility of prostate-specific antigen in the management of advanced prostate cancer.前列腺特异性抗原在晚期前列腺癌治疗中的应用。
BJU Int. 2013 Sep;112(5):548-60. doi: 10.1111/bju.12061. Epub 2013 Jul 4.
9
Update on the diagnosis and treatment of prostate cancer.
Curr Opin Oncol. 1998 May;10(3):244-52. doi: 10.1097/00001622-199805000-00012.
10
[Possible value of positive PSA levels in malignant and nonmalignant breast diseases].[前列腺特异抗原(PSA)阳性水平在乳腺良恶性疾病中的可能价值]
Onkologie. 2001 Feb;24 Suppl 1:11-7. doi: 10.1159/000055160.